<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008016</url>
  </required_header>
  <id_info>
    <org_study_id>Anaesthesia and Resuscitation</org_study_id>
    <nct_id>NCT05008016</nct_id>
  </id_info>
  <brief_title>Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.</brief_title>
  <official_title>Procalcitonin Level and the High Risk of Mortality in 30 Days , in Critically Ill Patients Infected by SARS-CoV-2, Experience of a North African Hospital University , Cases Series.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohammed VI University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mohammed VI University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory&#xD;
      Clinique cases specially patient with pulmonary bacterienne infection .&#xD;
&#xD;
      Materials and methods the investigatore had retrospectively reviewed the electronic records&#xD;
      and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI&#xD;
      , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and&#xD;
      mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of&#xD;
      severity and high mortality .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our objective is to assess the relationship between Procalcitonin and 30-day mortality in&#xD;
      patients admitted to the resuscitation department of the Mohammed VI University Hospital&#xD;
      Center, Oujda, Morocco, infected by the SARS COV 2 Virus .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procalcitonin is a marker of mortality</measure>
    <time_frame>through study completion, an average of 8 mounths</time_frame>
    <description>as a cutoff 0.5 ng/ml Procalcitonin could be used as mortality factors</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">582</enrollment>
  <condition>the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients</condition>
  <arm_group>
    <arm_group_label>Procalcitonine analysed</arm_group_label>
    <description>The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -582 patient with the SARS COV 2 virus, in the Resuscitation Service of the Mohammed VI&#xD;
        University Hospital Center oujda, MAroc&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of SARS COV2 infection needed admission in ICU .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient under 15 ans&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>younes Oujidi</name>
      <address>
        <city>Berkane</city>
        <zip>9999</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Morocco</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mohammed VI University Hospital</investigator_affiliation>
    <investigator_full_name>Younes Oujidi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>Procalcitonine</keyword>
  <keyword>Mortality</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

